[{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"||AChE","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Biogen"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ NeuraLight"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"PhaseV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ PhaseV","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ PhaseV"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Hannover Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Hannover Medical School","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Hannover Medical School"},{"orgOrder":0,"company":"SciSparc","sponsor":"Hannover Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Hannover Medical School","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Hannover Medical School"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Yale University"},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Yale University"},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Yale University"},{"orgOrder":0,"company":"Therapix Biosciences","sponsor":"Evero","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Therapix Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapix Biosciences \/ Evero","highestDevelopmentStatusID":"8","companyTruncated":"Therapix Biosciences \/ Evero"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Topoisomerase II\/Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 09, 2025

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 28, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.

                          Product Name : SCI-110

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 30, 2024

                          Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.

                          Product Name : SCI-110

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 23, 2024

                          Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is being developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.

                          Product Name : SCI-110

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 18, 2024

                          Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 10, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : PrimeC

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 07, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank